Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and-resistant human ovarian cancer cells

International Journal of Oncology

Volumn 43, Issue 4, 2013, Pages 1269-1280

  Marverti, Gaetano ^a   Ligabue, Alessio ^a   Lombardi, Paolo ^c   Ferrari, Stefania ^b   Monti, Maria Giuseppina ^a   Frassineti, Chiara ^a   Costi, Maria Paola ^b  

^a Metabolic and Neuroscience   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c Naxospharma Srl   (Italy)

Author keywords

Berberine; Cisplatin resistance; Dihydrofolate reductase; Polyamines; Spermidine spermine N1 acetyltransferase; Thymidylate synthase

Indexed keywords

ACYLTRANSFERASE; BERBERINE; CISPLATIN; DIHYDROFOLATE REDUCTASE; FOLIC ACID; POLYAMINE; SPERMIDINE SPERMINE N1 ACETYLTRANSFERASE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOSYNTHESIS; CANCER GROWTH; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; POLYAMINE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ACETYLTRANSFERASES; BERBERINE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; POLYAMINES; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE;

EID: 84882447813     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2045     Document Type: Article

References (61)

1. Ozols RF, Bookman MA, Connolly DC, et al: Focus on 433 epithelial ovarian cancer. Cancer Cell 5: 19-24, 2004.
2. Muggia F: Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol 112: 275-281, 2009.
3. Jakubowicz-Gil J, Paduch R, Piersual T, Glowniak K, Gawron A and Kandefer M: The effect of quercetin on pro-apoptotic activity of cisplatin in HeLa cells. Biochem Pharmacol 6: 1343-1350, 2005.
4. Maeda H, Hori S, Ohizumi H, Segawa T, Kakehi Y, Ogawa O and Kakizuka A: Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ 11: 737-746, 2004.
5. Umanzor J, Aguiluz M, Pineda C andrade S, Erazo M, Flores C and Santillana S: Concurrent cisplatin/gemcitabine chemotherapy along with radiotherapy in locally advanced cervical carcinoma: a phase II trial. Gynecol Oncol 100: 70-75, 2006.
6. Scanlon KJ and Kashani-Sabet M: Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells. Proc Natl Acad Sci USA 85: 650-653, 1988.
7. Wysocki PJ: Targeted therapy of hepatocellular cancer. Expert Opin Investig Drugs 19: 265-274, 2010.
8. Lin CC, Yang JS, Chen JT, et al: Berberine induces apoptosis in human HSC-3 oral cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway. Anticancer Res 27: 3371-3378, 2007.
9. Mantena SK, Sharma SD and Katiyar SK: Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther 5: 296-308, 2006.
10. Yoon MJ, So HS, Cho HJ, et al: Berberine, a natural product, combined with cisplatin enhanced apoptosis through a mitochondria/caspase-mediated pathway in HeLa cells. Biol Pharm Bull 31: 789-795, 2008.
11. Yi ZB, Yan Y, Liang YZ, et al: Evaluation of the antimicrobial mode of berberine by LC/ESI-MS combined with principal component analysis. J Pharm Biomed Anal 44: 301-304, 2007.
12. Liu JC, Chan P, Chen YJ, et al: The antihypertensive effect of the berberine derivative 6-protoberberine in spontaneously hypertensive rats. Pharmacology 59: 283-289, 1999.
13. Kuo CL, Chi CW and Liu TY: The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 203: 127-137, 2004.
14. Un Y, Xun K, Wang Y, et al: A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. Anticancer Drugs 20: 757-769, 2009.
15. Tang J, Feng Y, Tsao S, et al: Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol 126: 517, 2009.
16. Kong B, Huang S, Wang W, May D, et al: Arsenic trioxide induces apoptosis in cisplatin-sensitive and-resistant ovarian cancer cell lines. Int J Gynecol Cancer 15: 872-877, 2005.
17. Lin JP, Yang JS, Lee JH, Hsieh WT and Chung JG: Berberine induces cell cycle arrest and apoptosis in human gastric carcinoma SNU-5 cell line. World J Gastroenterol 12: 21-28, 2006.
18. Halestrap AP, Doran E, Gillespie JP and O'Toole A: Mitochondria and cell death. Biochem Soc Trans 28: 170-171, 2000.
19. Duverger V, Sartorius U, Klein-Bauernschmitt P, Krammer PH and Schlehofer JR: Enhancement of cisplatin-induced apoptosis by infection with adeno-associated virus type. Int J Cancer 97: 706-712, 2002.
20. Li JJ, Tang Q, Li Y, Hu BR, Ming ZY, Fu Q, Qian JQ and Xiang JZ: Role of oxidative stress in the apoptosis of hepatocellular carcinoma induced by combination of arsenic trioxide and ascorbic acid. Acta Pharmacol Sin 27: 1078-1084, 2006.
21. Jantova S, Cipak L and Letasiova S: Berberine induces apoptosis through a mitochondrial/caspase pathway in human promonocytic U937 cells. Toxicol n Vitro 21: 25-31, 2007.
22. Marverti G, Guaitoli G, Ligabue A, Frassineti C, Monti MG, Lombardi P and Costi MP: Distamycin A and derivatives as synergic drugs in cisplatin-sensitive and-resistant ovarian cancer cells. Amino Acids 42: 641-653, 2012.
23. Arcamone F, Pencos PG, Orezzi PG, Nicolella V and Pirelli AM: Structure and synthesis of distamycin A. Nature 203: 1064-1065, 1964.
24. Abu-Daya A and Fox KR: Interaction of minor groove binding ligands with long AT tracts. Nucleic Acids Res 25: 4962-4969, 1997.
25. Carreras CW and Santi DV: The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 64: 721-762, 1995.
26. Costi P and Ferrari S: Update on antifolate drugs targets. Curr Drug Targets 2: 135-166, 2001.
27. Choi W, Gerner EW, Ramdas L, et al: Combination of 5-fluorouracil and N1,N11-Diethylnorspermine markedly activates spermidine/spermine N1-acetyltransferase expression, depletes polyamines and synergistically induces apoptosis in colon carcinoma cells. J Biol Chem 280: 3295-3304, 2005.
28. Allen WL, McLean EG, Boyer J, et al: The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells. Mol Cancer Ther 6: 128-137, 2007.
29. Marverti G, Ligabue A, Guerrieri D, et al: Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and-resistant human ovarian cancer cell lines. Gynecol Oncol 117: 202-210, 2010.
30. Wallace HM and Niiranen K: Polyamine analogues-an update. Amino Acids 33: 261-265, 2007.
31. Wallace HM and Fraser AV: Inhibitors of polyamine metabolism: review article. Amino Acids 26: 353-365, 2004.
32. Marverti G, Monti MG, Pegg AE, et al: Spermidine/spermine N1-acetyltransferase transient over-expression restores sensitivity of resistant human ovarian cancer cells to N1,N12-bis(ethyl)spermine and to cisplatin. Carcinogenesis 26: 1677-1686, 2005.
33. Andrews PA, Murphy MP and Howell SB: Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res 45: 6250-6253, 1985.
34. Rossi T, Coppi A, Bruni E, Ruberto A, Santachiara S and Baggio G: Effects of anti-malarial drugs on MCF-7 and Vero cell replication. Anticancer Res 27: 2555-2560, 2007.
35. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folic phenol reagent. J Biol Chem 193: 265-275, 1951.
36. Kueng W, Siber E and Eppenberger U: Quantification of cells cultured on 96-well plates. Anal Biochem 182: 16-19, 1989.
37. van Triest B, Pinedo HM, van Hensbergen Y, et al: Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidilate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 5: 643-654, 1999.
38. Rothenberg SP, Perwaiz Iqbal M and Da Costa M: A simplified radioenzymatic assay for dihydrofolate reductase using [3H]dihydrofolate. Anal Biochem 103: 152-156, 1980.
39. Bradford MM: A rapid and sensitive method for quantification of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
40. Arocho A, Chen B, Ladanyi M and Pan Q: Validation of the 2-Ct calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts. Diagn Mol Pathol 15: 56-61, 2006.
41. Kansara V, Paturi D, Luo S, Gaudana R and Mitra AK: Folic acid transport via high affinity carrier-mediated system in human retinoblastoma cells. Int J Pharm 355: 210-219, 2008.
42. Casero RA Jr, Gabrielson EW and Pegg AE: Immunohistochemical staining of spermidine/spermine N1-acetyltransferase superinduced in response to treatment with antitumour polyamine analogues. Cancer Res 54: 3955-3958, 1994.
43. Chou TC and Talalay P Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. In: Advances in Enzyme Regulation. Weber G (ed.) Pergamon Press, New York, NY, pp27-55 1984.
44. Marverti G, Ligabue A, Paglietti G, et al: Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells. Eur J Pharmacol 615: 17-26, 2009.
45. Chu E and Allegra CJ: The role of thymidylate synthase as an RNA binding protein. Bioessays 18: 191-198, 1996.
46. Marverti G, Piccinini G, Ghiaroni S, Barbieri D, Quaglino D and Moruzzi MS: N1,N12-bis(ethyl)spermine effect on growth of cis- diamminedichloroplatinum(II)-sensitive and-resistant human ovarian carcinoma cell lines. Int J Cancer 78: 33-40, 1998.
47. Orfila L, Rodriguez M, Colman T, Hasegawa M, Merentes E and Arvelo F: Structural modification of berberine alkaloids in relation to cytotoxic activity in vitro. J Ethnopharmacol 71: 449-456, 2000.
48. Gong GQ, Zong ZX and Song YM: Spectrofluorometric determination of DNA and RNA with berberine. Spectrochimica Acta A Mol Biomol Spectrosc 55: 1903-1907, 1999.
49. Debnath D, Suresh Kumar G, Nandi R and Maiti M: Interaction of berberine chloride with deoxyribonucleic acids: evidence for base and sequence specificity. Indian J Biochem Biophys 26: 201-208, 1989.
50. Bhadra K, Maiti M and Suresh Kumar G: Berberine-DNA complexation: new insights into the cooperative binding and energetic aspects. Biochim Biophys Acta 1780: 1054-1061, 2008.
51. Tan W, Li Y, Chen M and Wang Y: Berberine hydrochloride: anticancer activity and nanoparticulate delivery system. Int J Nanomedicine 6: 1773-1777, 2011.
52. Maiti M and Kumar GS: Polymorphic nucleic acid binding of bioactive isoquinoline alkaloids and their role in cancer. J Nucleic Acids 2010: 1-23, 2010.
53. Bhadra K and Kumar GS: Therapeutic potential of nucleic acid-binding isoquinoline alkaloids: binding aspects and implications for drug design. Med Res Rev 31: 821-862, 2011.
54. Ferraroni M, Bazzicalupi C, Bilia AR and Gratteri P: X-ray diffraction analyses of the natural isoquinoline alkaloids Berberine and Sanguinarine complexed with double helix DNA d(CGTACG). Chem Commun 47: 4917-4919, 2011.
55. Bhowmik D, Hossain M, Buzzetti F, D'Auria R, Lombardi P and Kumar GS: Biophysical studies on the effect of the 13 position substitution of the anticancer alkaloid berberine on its DNA binding. J Phys Chem B 116: 2314-2324, 2012.
56. Cho J and Rando RR: Specific binding of Hoechst 33258 to site 1 thymidylate synthase mRNA. Nucleic Acids Res 28: 2158-2163, 2000.
57. Mazzini S, Bellucci MC and Mondelli R: Mode of binding of the cytotoxic alkaloid berberine with the double helix oligonucleotide d(AAGAATTCTT)2. Bioorg Med Chem 11: 505-514, 2003.
58. Hiraku Y, Oikawa S and Kawanishi S: Distamycin A, a minor groove binder, changes enediyne-induced DNA cleavage sites and enhances apoptosis. Nucleic Acids Res (Suppl) 2: 95-96, 2002.
59. Basu S, Feuerstein BG, Dennis FD, Lubich WP, Bergeron RJ, Samejima K and Marton LJ: Correlation between the effects of polyamine analogues on DNA conformation and cell growth. Cancer Res 49: 5591-5597, 1989.
60. Agostinelli E, Arancia G, Dalla Vedova L, Belli F, Marra M, Salvi M and Toninello A: The biological functions of polyamine oxidation products by amine oxidases: perspectives of clinical applications. Amino Acids 27: 347-358, 2004.
61. Sun D, Wollin A and Stephen AM: Moderate folate deficiency influences polyamine synthesis in rats. J Nutr 132: 2632-2637, 2002.